Cargando…

The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma

BACKGROUND: Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear. METHODS: We summarized the clinical data of 57 PAM patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Haibo, Miao, Yazhou, Shen, Yutao, Guo, Jing, Xie, Weiyan, Zhao, Sida, Dong, Wei, Zhang, Yazhuo, Li, Chuzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821033/
https://www.ncbi.nlm.nih.gov/pubmed/31665029
http://dx.doi.org/10.1186/s12967-019-2103-0
_version_ 1783464071564099584
author Zhu, Haibo
Miao, Yazhou
Shen, Yutao
Guo, Jing
Xie, Weiyan
Zhao, Sida
Dong, Wei
Zhang, Yazhuo
Li, Chuzhong
author_facet Zhu, Haibo
Miao, Yazhou
Shen, Yutao
Guo, Jing
Xie, Weiyan
Zhao, Sida
Dong, Wei
Zhang, Yazhuo
Li, Chuzhong
author_sort Zhu, Haibo
collection PubMed
description BACKGROUND: Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear. METHODS: We summarized the clinical data of 57 PAM patients and compared with sporadic pituitary adenoma (SPA) and sporadic meningioma (SM). 5 pituitary adenomas of PAM and 5 SPAs were performed ceRNA microarray. qRT-PCR, Western Blot, siMEN1 and rapamycin inhibition experiment were validated for ceRNA microarray. RESULTS: Clinical variable analyses revealed that significant correlations between PAM and female sex as well as older age when compared with SPA and significant correlations between PAM and transitional meningioma as well as older age when compared with SM. Additionally, the characteristics of PAM were significantly different for MEN1 patients. Functional experiments showed lower expression of MEN1 can upregulate mTOR signaling, in accordance with the result of ceRNA microarray. Rapamycin treatment promotes apoptosis in primary pituitary adenoma and meningioma cells of PAM. CONCLUSIONS: MEN1 plays an important role in PAM by upregulating mTOR signaling pathway. Rapamycin represents a potential therapeutic strategy for PAM in the future.
format Online
Article
Text
id pubmed-6821033
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68210332019-11-04 The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma Zhu, Haibo Miao, Yazhou Shen, Yutao Guo, Jing Xie, Weiyan Zhao, Sida Dong, Wei Zhang, Yazhuo Li, Chuzhong J Transl Med Research BACKGROUND: Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear. METHODS: We summarized the clinical data of 57 PAM patients and compared with sporadic pituitary adenoma (SPA) and sporadic meningioma (SM). 5 pituitary adenomas of PAM and 5 SPAs were performed ceRNA microarray. qRT-PCR, Western Blot, siMEN1 and rapamycin inhibition experiment were validated for ceRNA microarray. RESULTS: Clinical variable analyses revealed that significant correlations between PAM and female sex as well as older age when compared with SPA and significant correlations between PAM and transitional meningioma as well as older age when compared with SM. Additionally, the characteristics of PAM were significantly different for MEN1 patients. Functional experiments showed lower expression of MEN1 can upregulate mTOR signaling, in accordance with the result of ceRNA microarray. Rapamycin treatment promotes apoptosis in primary pituitary adenoma and meningioma cells of PAM. CONCLUSIONS: MEN1 plays an important role in PAM by upregulating mTOR signaling pathway. Rapamycin represents a potential therapeutic strategy for PAM in the future. BioMed Central 2019-10-29 /pmc/articles/PMC6821033/ /pubmed/31665029 http://dx.doi.org/10.1186/s12967-019-2103-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhu, Haibo
Miao, Yazhou
Shen, Yutao
Guo, Jing
Xie, Weiyan
Zhao, Sida
Dong, Wei
Zhang, Yazhuo
Li, Chuzhong
The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma
title The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma
title_full The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma
title_fullStr The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma
title_full_unstemmed The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma
title_short The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma
title_sort clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821033/
https://www.ncbi.nlm.nih.gov/pubmed/31665029
http://dx.doi.org/10.1186/s12967-019-2103-0
work_keys_str_mv AT zhuhaibo theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT miaoyazhou theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT shenyutao theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT guojing theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT xieweiyan theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT zhaosida theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT dongwei theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT zhangyazhuo theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT lichuzhong theclinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT zhuhaibo clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT miaoyazhou clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT shenyutao clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT guojing clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT xieweiyan clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT zhaosida clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT dongwei clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT zhangyazhuo clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma
AT lichuzhong clinicalcharacteristicsandmolecularmechanismofpituitaryadenomaassociatedwithmeningioma